The objective of this study is to determine the ability of cell free tumor DNA genomic profiling to predict disease relapse or progression while on therapy for advanced stage NSCLC in comparison to current standard objective measures of disease relapse or progression.
This study is a prospective observational study. The investigators will assess whole genome sequencing from patient blood samples collected alongside routine blood draws with each treatment cycle to determine the tumor load score at each timepoint while on therapy. CT images will be obtained at routinely ordered timepoints throughout therapy and will be used in the assessment for standard clinical or radiographic evidence of disease progression. These methods of measuring disease progression will be compared in a lead time analysis.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Treatment naïve biopsy confirmed not surgically resectable stage III or greater NSCLC
Baseline CT imaging available
You may not be if
Patients unable to undergo biopsy for initial tissue diagnosis
Patients who do not wish to pursue standard of care therapy
